Literature DB >> 7887073

Cytologic diagnosis of rhabdomyosarcoma in a patient with germ cell tumor. A case report.

Y T Kaw1, H M Cramer.   

Abstract

The development of sarcomas in patients with germ cell tumors is rare but has been reported previously. Theories about its pathogenesis include derivation of the tumor cells from pluripotential germ cells and malignant transformation from teratomatous elements. This report describes the occurrence of rhabdomyosarcoma in a patient with a history of mixed germ cell tumor of the testis who developed a malignant pleural effusion. Cytologic evaluation of the fluid revealed single malignant cells with high nuclear/cytoplasmic ratios and prominent nucleoli. While these features initially suggested a diagnosis of metastatic seminoma, careful cytologic and immunohistochemical examination revealed features consistent with metastatic rhabdomyosarcoma. The exfoliative cytologic findings of other germ cell tumors are also discussed.

Entities:  

Mesh:

Year:  1995        PMID: 7887073

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  4 in total

1.  A case of testicular rhabdomyosarcoma.

Authors:  M Erkan Erbay; Fatih Tarhan; Nagehan Ozdemir Barişik; Uğur Kuyumcuoğlu
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

2.  Mixed germ cell tumor of the testicle with ravdomuosarcomatous component: a case report.

Authors:  Konstantinos Stamatiou; Panagiotis Papadopoulos; Georgios Perlepes; Nikolaos Galariotis; Michalis Olympitis; Hippocrates Moschouris; Theodora Vasilakaki
Journal:  Cases J       Date:  2009-12-10

Review 3.  Primary intratesticular rhabdomyosarcoma in children: a case report and review of the literature.

Authors:  James J Yahaya; Alex Mremi
Journal:  J Med Case Rep       Date:  2021-01-31

Review 4.  Serous fluid: Metastatic sarcomas, melanoma, and other non-epithelial neoplasms.

Authors:  Liron Pantanowitz; Mamatha Chivukula
Journal:  Cytojournal       Date:  2022-03-19       Impact factor: 2.345

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.